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Objective: High oxidative stress potentially leads to accelerated telomere shortening and consequent
premature cell senescence, implicated in type 2 diabetes (T2D) development. Therefore, we studied the
association of leukocyte telomere length (LTL) with the presence of T2D, as well as the effect on the
patients’ LTL of plasma oxidative stress and of variation in UCP2, a gene involved in the mitochondrial
production of reactive oxygen species.
Methods: Mean LTL was determined in 569 Caucasian, 103 South Asian and 70 Afro-Caribbean T2D
patients aged from 24 to 92 years, 81 healthy Caucasian male students aged from 18 to 28 years and
367 healthy Caucasian men aged from 40 to 61 years by real-time PCR. Plasma total antioxidant status
(TAOS)wasmeasured in the T2Dpatients by a photometricmicroassay. The patientswere also genotyped
for the UCP2 functional variants −866G>A and A55V.
Results: Afro-Carribeans had 510bp longer mean length compared to Caucasians (p<0.0001) and 500bp
longer than South Asians (p=0.004). T2D subjects displayed shorter age-adjusted LTL compared to
controls [6.94(6.8–7.03) vs. 7.72(7.53–7.9), p<0.001] with subjects in the middle and the lowest ter-
tile of LTL having signiﬁcantly higher odds ratios for T2D compared to those in the highest tertile
[1.50(1.08–2.07) and 5.04(3.63–6.99), respectively, p<0.0001]. In the patients, LTL was correlated nega-
tivelywith age (r=−0.18, p<0.0001) and positivelywith TAOSmeasures (r=0.12, p=0.01) after adjusting
for age, while carriers of theUCP2 −866A allele had shorter age-adjusted LTL than common homozygotes
[6.86(6.76–6.96) kb vs. 7.03(6.91–7.15) kb, p=0.04].
Conclusion: The present data suggest that shorter LTL is associated with the presence of T2D and this
could be partially attributed to the high oxidative stress in these patients. The association of the UCP2
functional promoter variant with the LTL implies a link between mitochondrial production of reactive
er teloxygen species and short
. Introduction
Premature cell senescence has recently been postulated as an
mportant cause and consequence of type 2 diabetes (T2D) and
ts complications [1]. The telomere shortening hypothesis is a
idely accepted mechanism leading to senescence [2]. Telomeres
re specialised DNA-protein structures at the end of all chro-
osomes, which preserve chromosome stability and integrity. In
umans they consist of thousandsof tandemrepeats of theTTAGGG
equence [3]. Telomeres shortenwith cell divisionandcells are trig-
∗ Corresponding author. Tel.: +44 20 7679 6337; fax: +44 20 7679 6212.
E-mail address: k.salpea@ucl.ac.uk (K.D. Salpea).
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gered into senescence once mean length reduces below a critical
value [2].
Telomere attrition is mainly caused by the “end-replication”
problem, generated by the incapability of DNA polymerase to fully
copy the very end of the lagging strand [4]. Another factor con-
tributing to telomere attrition involves the processing of telomere
ends to reconstitute 3′ single-strand overhangs, and telomere loss
due to the fact that DNA repairmechanisms, particularly for single-
stranded DNA damage, are less efﬁcient in telomeric DNA than
elsewhere in the genome. The resulting accumulation of single-
Open access under CC BY-NC-ND license.strandbreaks along the telomeres leads toDNAdamage-dependent
shortening during replication [5]. Hence, telomere shortening
could serve as an indicator of replicative history and cumulative
genomic damage of somatic cells. Telomeric DNA is particularly
prone to oxidative damage at the GGG sequence. Exposure to free
roscler
r
b
[
e
o
i
g
p
m
t
d
s
t
T
a
t
s
t
t
c
[
o
p
t
d
t
a
t
e
g
n
m
s
l
p
a
t
s
t
b
S
i
t
s
t
t
w
t
e
2
2
2
d
a
t
c
p
rK.D. Salpea et al. / Athe
adicals or oxidants causes DNA damage including single-strand
reaks and telomere erosion as shown with in vitro experiments
6–8]. Therefore, it is speculated that the rate of telomere short-
ning will be dependent on the balance between intracellular
xidative stress and antioxidant defence.
Prediabetes and metabolic syndrome are associated with
ncreased oxidative stress [9,10]. It is well established that hyper-
lycaemia elicits an increase in reactive oxygen species (ROS)
roduction, due to increased input of reducing equivalents into the
itochondrial electron transport chain. ROS overproduction is a
rigger for pathways responsible for hyperglycaemia-induced cell
amage [11,12].
Our hypothesis is that shorter telomeres eventually lead to
enescent phenotypes in multiple cell types including beta cells,
he consequent apoptosis of which hastens the onset of diabetes.
hese shorter telomeres can be either attributed to shorter length
t birth in individuals predisposed to diabetes or to accelerated
elomere loss during cell division caused by increased oxidative
tress in prediabetic conditions, or both. In support of this, shorter
elomeres have been observed in circulating epithelial progeni-
or cells in patients with metabolic syndrome [13] and in other
onditions of high oxidative stress, such as smoking and obesity
14]. The data on T2D and telomere length though are scarce with
nly few small studies with up to 80 subjects showing that T2D
atients have shorter telomeres than controls [15–17]. Whether
his is due to oxidative stress, and to what degree, remains to be
etermined. Therefore, our aim was to examine the association of
elomere length with the presence of T2D in a large cohort as well
s the effect of plasma oxidative stress on the patients’ leukocyte
elomere length.
In order to further enlighten the effect of ROS on telomere short-
ning, we also studied the effect of uncoupling protein 2 (UCP2)
ene variation. This ubiquitously expressed protein is a plausible
egative regulator of ROS production, since it dissipates the inner
itochondrialmembrane electrochemical gradient that drives ATP
ynthesis and uncouples respiration from oxidative phosphory-
ation [18]. Decreased UCP2 expression results in increased ROS
roduction, in vitro [19], while animal studies have shown that
bsence of UCP2 causes higher oxidative stress [20]. To main-
ain homeostasis, UCP2 expression is induced by elevated oxygen
pecies concentration [21]. A common functional variant exists in
he promoter of human UCP2 gene (−866G>A), with the A allele
eing associatedwith lowermRNA levels,while anon-synonymous
NP leading to analanine tovaline substitutionhasbeen indentiﬁed
n exon 4 of the gene (A55V) [22]. A previous study fromour labora-
ory, demonstrated that the UCP2 −866G>A variant interacts with
moking to increase oxidative stress in T2D patients [23]. Given
his ﬁnding and the established function of UCP2, we hypothesised
hat these functional variants in the UCP2 gene will be associated
ith the stress-induced telomeric DNA damage and therefore with
he telomere length of T2D patients, in whom oxidative stress is
levated.
. Materials and methods
.1. Subjects
.1.1. University College London Diabetes and Cardiovascular
isease Study (UDACS)
The UDACS is a cross-sectional sample of diabetes patients,ccording to the World Health Organization criteria [24], designed
o study the association between commongenetic variants andbio-
hemical risk factors implicated in coronary heart disease (CHD) in
atients with diabetes. It comprises of 1011 subjects consecutively
ecruited from the diabetes clinic at UCL Hospitals in 2001–2. Anal-osis 209 (2010) 42–50 43
yses were conﬁned only to T2D patients (N=742). Ethical approval
was obtained from UCL/UCL Hospitals ethics committee and all
subjects gave informed consent. The full characteristics of patients
have been reported previously [25].
2.1.2. European Atherosclerosis Research Study II (EARS II)
The EARSII was carried out in 1993. Male students between the
ages of 18 and 28 years whose fathers had a proven myocardial
infarction before the age of 55 (cases, N=407) and age-matched
male controls (N=415) were recruited from 14 university student
populations of 11 European countries: Tallinn in Estonia, Helsinki
and Oulu in Finland were designated Baltic; Glasgow, Belfast and
Bristol were designated United Kingdom (UK); Aarhus in Denmark,
Hamburg in Germany, Ghent in Belgium, and Zurich in Switzerland
were designated Middle Europe; Lisbon in Portugal, Reus in Spain,
Naples in Italy, andAthens inGreeceweredesignatedSouthEurope.
Only the controls were considered in the present study. The study
has been approved by ethics committees of collaborating centres
and the subjects have given informed consent. Details of the study
have been described previously [26].
2.1.3. Hypercoagulability and Impaired Fibrinolytic function
MECHanisms predisposing to myocardial infarction (HIFMECH)
The HIFMECH study consists of 598 male survivors of a ﬁrst
myocardial infarction aged <60 years (excluding patients with
familial hypercholesterolaemia and insulin-dependent diabetes
mellitus) and 653 population-based control subjects of the same
age and region recruited from four centers in Europe: Stockholm
in Sweden and London in England were designated North Europe
and Marseille in France and San Giovanni Retondo in Italy were
designated South Europe. The study has been approved by ethics
committees of collaborating centres and the subjects have given
informed consent. Detailed description of the study can be found
elsewhere [27].
2.2. Determination of plasma total antioxidant status (TAOS)
The UDACS plasma samples were collected within a 12-month
period and stored immediately at −80 ◦C. A modiﬁcation by Samp-
son of Laight’s photometric microassay [28] was used to measure
plasma TAOS. In this method, plasma TAOS is determined by its
capacity to inhibit the peroxidase-mediated formation of the 2,2-
azino-bis-3-ethylbensthiazoline-6-sulfonic acid radical. The assay
is performed in a 96-well ELISA plate with 2.5L of plasma. The
inter-assay coefﬁcient of variation was 14% and the intra-assay
4.3%. In general terms, increased oxidative stress within a sam-
ple is negatively correlated with consumption of antioxidants and
diminished antioxidant status within that sample.
In order to test whether TAOS is a valid measure of oxida-
tive stress, we have previously examined the correlation between
plasma TAOS and esteriﬁed F2-isoprostane and found this to be
signiﬁcant (r=−0.65; p=0.003) [29]. Since the measures obtain by
the twomethods correlate, the inter-individual differences in TAOS
and/or the correlation to other variables is feasible by using either
method.
2.3. Determination of leukocyte telomere length
Leukocyte DNA was extracted by the salting-out method [30].
Telomere length was measured in these DNA samples using a vali-
dated quantitative PCR-basedmethod as previously described [26].
Brieﬂy, the relative telomere length was calculated as the ratio of
telomere repeats to single-copy gene (SCG) copies (T/S ratio). For
each sample the quantity of telomere repeats and the quantity of
SCG copies were determined in comparison to a reference sample
in a telomere and a SCG quantitative PCR, respectively. The raw
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ata from each PCR was analysed using the comparative quantiﬁ-
ation analysis (Rotor-Gene 6000 software, Corbett Research Ltd.,
ambridge, UK). All PCRs were performed on the Rotor-Gene 6000
Corbett Research Ltd., Cambridge, UK). The coefﬁcient of variation
n repeated measurements was 5.6%. Using the linear regression
ine between measures obtained by both the PCR-based method
nd the conventional terminal restriction fragment (TRF) analysis
or the same set of 32 samples, as previously described, we calcu-
ated the corresponding telomere length in bp from the T/S ratio
easured in each subject [26].
.4. Functional UCP2 single-nucleotide polymorphism (SNP)
enotyping
The −866G>A promoter variant and the non-synonymous A55V
ariant of the UCP2 gene were genotyped using TaqMan Assay-by-
esignplatform(AppliedBiosciences,ABI,Warrington,UK). FiveL
eactions were performed on 384-well microplates and analysed
sing the ABI TaqMan 7900HT software (probe details available on
equest).
.5. Statistical analysis
Statistical analysis was performed with SPSS statistical soft-
are (version 15.0 for Windows). Baseline characteristics were
ransformed to a normal distribution where appropriate. To com-
are telomere length in T2D cases and controls, mean values were
djusted to an age of 68 years (the mean age in the T2D cases)
or all studies. Odds ratios were calculated from logistic regression
odels using telomere length both as a continuous variable and
fter dividing it into tertiles. The tertiles of telomere length were
ig. 1. (A) Ethnic differences in mean age-adjusted leukocyte telomere length (LTL) of
eukocyte telomere length (LTL).osis 209 (2010) 42–50
constructed using the combined case–control group with the age-
adjustment made within the separate groups. Partial correlation
coefﬁcients were used to examine the association between telom-
ere length and continuous classical risk factors after adjustment for
age (when testing the correlationwith age, telomere lengthwasnot
age-adjusted). To examine the associations of age-adjusted telom-
ere length and glucose with TAOS, the Spearman’s rho correlation
coefﬁcient was calculated. Differences in telomere length between
ethnic groups, tertiles of TAOS, categorical characteristics andUCP2
SNP genotypes were tested using analysis of covariance. All mod-
els used to test the differences in telomere length were adjusted
for age. In each case of UCP2 SNP all three possible models (addi-
tive, dominant and recessive) were tested and the best ﬁtted one
was chosen by the higher R2 of the test. The differences in TAOS
among the UCP2 SNP genotypes were tested with Kruskall–Wallis
or Mann–Whitney U-tests. A nonparametric test for trend (per-
formed with STATA, Version 9, StataCorp, TX, USA) was also
used to examine these differences. Haplotypes were inferred after
excluding individuals with missing values using THESIAS software
(http://www.genecanvas.org). Haplotypes with frequency of less
than2%were excluded from the analysis. Resultswere presented as
the geometricmean telomere length (95% CI) for two copies of each
haplotypeassumingamultiplicative effect and themeanTAOS (95%
CI) assuming an additive effect. Statistical signiﬁcancewas taken as
p<0.05.
In the present study a speciﬁc a priori hypothesis was tested.
Therefore, we believe adjustment for multiple comparisons is not
necessary. We and others [31] support that correction for multi-
ple comparisons is too conservative inhypothesis-deriving analysis
such as this and has also been suggested to lead to errors in inter-
pretation [32].
the type 2 diabetes patients. (B) Case–control differences in mean age-adjusted
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Table 1
Characteristics of the Caucasian 2 diabetes cases and controls.
UDACS T2D cases N=569 EARSII controls N=81 HIFMECH controls N=367
Age (years), median [range] 68 [24–92] 21 [18–28] 53 [40–61]
Age of T2D onset (years) 55 (13)
Duration of T2D (years)a 9 [4–16]
% Males (N) 59.4 (338) 100 (81) 100 (367)
% Females (N) 40.6 (231) 0 (0) 0 (0)
% Females >50 years (N) 94.4 (218)
BMI (kg/m2)b 29.3 (5.5) 23.0 (2.4) 25.6 (3.1)
SBP (mmHg)b 140.5 (20.9) 112.6 (9.8) 127.1 (15.3)
DBP (mmHg)b 79.3 (11.4) 66.0 (7.6) 82.8 (8.0)
Total cholesterol (mmol/l)b 4.96 (1.09) 4.06 (0.70) 5.50 (0.96)
TG (mmol/l)b 1.92 (1.08) 0.93 (0.35) 1.40 (0.60)
HDL (mmol/l)b 1.28 (0.37) 1.17 (0.20)
LDL (mmol/l)c 2.71 (0.94) 2.38 (0.60)
CRP (mg/l)b 1.72 (1.49) 0.59 (0.68) 1.08 (1.38)
TAOS (%)a 44.7 [35.4–52.4]
Glucose (mmol/l)b 9.8 (4.3) 5.20 (0.37)
HBA1c (%)b 7.65 (1.61)
% Hypertension (N) 83.4 (472) 0 (0) 4.2 (15)
% Ex/current smokers (N) 52.3 (291) 38.3 (31) 60.8 (223)
Hypoglycaemics
% None (N) 11.2 (63)
% Insulin (N) 13.1 (74) 0 (0) 0 (0)
% Oral (N) 62.6 (353)
% Both (N) 13.1 (74)
% BP lowering drug use (N) 68.6 (387) 0 (0) 0 (0)
% Aspirin use (N) 50.6 (285) 0 (0) 0 (0)
% Statin use (N) 31.6 (177) 0 (0) 0 (0)
Telomere length (kb)d 6.94 (6.80–7.03) 8.27 (7.62–9.00) 7.58 (7.39–7.81)
TG: triglycerides, HDL: high density lipoprotein, LDL: density lipoprotein, BMI: body mass index, CRP: C-reactive protein, SBP: systolic blood pressure, DBP: diastolic blood
pressure, TAOS: total antioxidant status.
a
d.
ulate
3
3
3
i
t
C
[
r
6
d
d
c
a
a
a
t
y
3
i
L
E
f
o
gMedian [IQR] is presented.
b Data were log-transformed and geometric mean (approx SD) is presented.
c Data were square root transformed and square of mean (approx SD) is presente
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. Results
.1. Study cohorts – ethnic/geographical diversity
.1.1. UDACS T2D cases
Leukocyte mean telomere length was successfully determined
n 742 T2D patients. Signiﬁcant differences were found among
he three ethnicities, after adjusting for age (p<0.0001). Afro-
arribeans had 510bp longermean length compared to Caucasians
7.46 (95%CI: 7.21–7.71) and 6.94 (95%CI: 6.80–7.03), p<0.0001,
espectively] and 500bp longer than South Asians [6.96 (95%CI:
.78–7.09), p=0.004], while Caucasians’ and South Asians’ length
id not differ signiﬁcantly (p=1.00) (Fig. 1A). Due to these ethnic
ifferencesand inorder toallowthecomparisonwith theCaucasian
ontrols, we used only the 569 Caucasian T2D cases in all further
nalysis. The cases’ characteristics are presented in Table 1. These
re typical of T2D patients with a mean age of 68 [24–92] years,
mean age of diabetes onset of 55 [13] years and the majority of
hem (59.4%) being males. The duration of diabetes was 9 [4–16]
ears and their BMI 29.3 (5.5) kg/m2.
.1.2. EARSII controls
The control subjects from two different studies were employed
n an effort to cover the large age range of the cases (24–92 years).
eukocyte telomere length was measured in 396 controls from the
ARSII study aged between 18 and 28 years recruited from 4 dif-
erent European regions. In our previous article on EARSII [26] we
bserved signiﬁcant differences in telomere length among the geo-
raphical regions of Europe. Therefore, we used for the presentthe corresponding telomere length inkb. Telomere lengthpresented is age-adjusted.
analysis only the 81 UK region controls to match the UDACS Cau-
casian patients which were recruited in the UK (Table 1).
3.1.3. HIFMECH controls
Leukocyte telomere length was also measured in 520 HIFMECH
controls with an age range of 40–61 years recruited from the North
and the Southpart of Europe. Again, due to the differences in telom-
ere length foundbetween theSouthand theNorth [8.27(4.14) kbvs.
7.99(4.51) kb, p=0.02] we only used in the present analysis the 367
controls from the North of Europe matching to the UK Caucasian
cases of UDACS (Table 1).
3.2. Case–control differences
The cases [6.94(6.80–7.03)] displayed shorter age-
adjusted leukocyte telomere length compared to the EARSII
[8.27(7.62–9.00), p<0.001] and the HIFMECH controls
[7.58(7.39–7.81), p<0.001] as well as the two control samples
combined [7.72(7.53–7.90), p<0.001] (Table 1, Fig. 1B).
Decreasing age-adjusted telomere length was associated with
a higher odds ratio for T2D when comparing the cases to
the EARSII controls [2.96(2.16–4.06), p<0.001], the HIFMECH
controls [1.88(1.58–2.24), p<0.001] and the combined controls
[2.38(1.45–3.89), p<0.001] (Fig. 2A). To better illustrate this effect
we divided the age-adjusted telomere length in tertiles. Subjects in
the middle and the lowest tertile of length had signiﬁcantly higher
odds ratios for T2D compared to thehighest tertile [1.50(1.08–2.07)
and 5.04(3.63–6.99) respectively, p<0.0001], with the effect being
more pronounced between lowest and highest tertiles (Fig. 2B).
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.3. Telomere length determinants in T2D patients
.3.1. Association with classical risk factors
As expected, there was a signiﬁcant negative correlation with
ge (r=−0.18,p<0.0001, Table 2 and Supplemental Fig. 1A). Telom-
re length was therefore age-adjusted in all further analyses.
able 2
orrelation coefﬁcients of age-adjusted telomere length with classical risk factors
n Caucasian type 2 diabetes patients.
Correlation coefﬁcient, r p-Value N
Age (years) −0.18 <0.0001 569
Age of onset (years) −0.01 0.77 569
Duration of diabetes (years) 0.01 0.77 569
BMI (kg/m2) 0.02 0.64 563
SBP (mmHg) 0.05 0.27 566
DBP (mmHg) −0.03 0.51 566
Total cholesterol (mmol/l) 0.03 0.41 566
TG (mmol/l) −0.03 0.44 566
HDL (mmol/l) 0.04 0.40 566
LDL (mmol/l) 0.05 0.25 549
CRP (mg/l) −0.05 0.21 555
TAOS (%) 0.12, 0.01 561
Glucose (mmol/l) −0.02 0.59 566
HBA1c (%) 0.01 0.77 563
G: triglycerides, HDL: high density lipoprotein, LDL: density lipoprotein, BMI: body
ass index, CRP: C-reactive protein, SBP: systolic blood pressure, DBP: diastolic
lood pressure, TAOS: total antioxidant status.djusted telomere length when comparing the cases with (i) the HIFMECH controls,
es for each tertile of age-adjusted telomere length when comparing the cases with
Age-adjusted telomere length was not correlated with any of
the classical clinical and biochemical factors measured in this
study (Table 2). There was no signiﬁcant difference in length
betweenmales and females, betweenpatientswithdifferent smok-
ing history, or between hypertensive and normotensive subjects.
Interestingly, we did not ﬁnd any signiﬁcant association with the
age of onset nor the duration of diabetes. The use of hypoglycaemic
drugs, blood pressure lowering drugs, aspirin or statin was also not
associated with length (Supplemental Table 1).
3.3.2. Association with plasma oxidative stress
There was a signiﬁcant positive correlation of the mean length
with continuous TAOSmeasurements (r=0.12, p=0.01, Table 2 and
Supplemental Fig. 1B). While TAOS measures were negatively cor-
related with glucose (r=−0.13, p=0.002), as expected. To further
examine this effect, TAOS measures were categorised in tertiles.
Individuals in the low tertile had signiﬁcantly shorter telomeres
[6.81 (95%CI: 6.68–6.94) kb] compared to those in the middle
and high tertiles of TAOS [6.99 (95%CI: 6.89–7.09) kb, p=0.04,
Fig. 3A].
3.3.3. Association with UCP2 functional variants
Among the 569 Caucasian T2D patients, genotype was obtainedin 566 (99.5%) for the −866G>A SNP and in 544 (95.6%) for the
exon 4 variant A55V (Table 3). The genotype distribution for
both the −866G>A and the A55V variants was as expected from
Hardy–Weinberg equilibrium (2 =0.50, p=0.48 and 2 =0.06,
p=0.30, respectively).
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aucasian type 2 diabetes patients carrying or not the UCP2 −866G>A variant. (The
rror bars represent 95% conﬁdence intervals.)
As shown in Table 3, carriers of the −866A allele had ∼170bp
2.4%) shorter mean length than the GG subjects (Fig. 3B) and
here was a trend to lower TAOS towards in these −866A allele
arriers. The effect of the −866A allele on TAOS was statistically
igniﬁcant among smokers of the present cohort, as previously
hown[23]. TheA55Vaminoacid changewasassociatedwith lower
AOS measures, but the effect on telomere length was not signiﬁ-
ant (Table 3). Haplotype analysis using these SNPs in combination
able 3
ge-adjusted telomere length and plasma total antioxidant status (TAOS) measures by UC
UCP2 SNP/haplotype %Genotype/haplotype (N) Telomere length
−866G>A (rs659366)
GG 40.8 (231) 7.03 (6.91–7.1
GA 46.5 (263) 6.86 (6.75–6.9
AA 12.7 (72) 6.84 (6.63–7.0
GA/AA 59.2 (335) 6.86 (6.76–6.9
A55V (rs660339)
CC 35.5 (193) 7 (6.86–7.14)
CT 48.4 (263) 6.9 (6.79–7.02
TT 16.2 (88) 6.8 (6.62–6.99
CT/TT 64.5 (351) 6.87 (6.78–6.9
−866G>A/A55Vc
G/C 63.0 6.98 (6.83–7.1
G/T 4.0 6.89 (6.06–7.9
A/T 33.0 6.79 (6.56–7.0
ll haplotypes with frequency <2% are excluded from the analysis.
a Data were log-transformed and the geometric mean (95%CI) was then used to calcula
b median [IQR] is presented.
c Data is presented for 2 copies of each haplotype.osis 209 (2010) 42–50 47
did not detect a statistically signiﬁcant effect on telomere length
(Table 3).
4. Discussion
The present study is the largest to date to demonstrate that
leukocyte telomere length is signiﬁcantly shorter in T2D patients
compared to controls over a wide age range, and that the shorter
telomeres in patients can be partially attributed to high oxidative
stress. We also report for the ﬁrst time an association of shorter
leukocyte telomeres in T2D patients with variation affecting the
UCP2 gene expression.
The T2D patients had on average 780bp shorter telomeres
than healthy individuals, a difference which represents a biolog-
ical age gap of approximately 24 years. This difference in leukocyte
telomere length between T2D cases and controls is greater than
the previously reported 500bp difference in Caucasians [15] but
smaller compared to the 3.1 kb difference found in an Asian Indian
cohort [17]. The discrepancy of the effect size on telomeres might
be due to the small sample size of these other studies but also,
in the second case, might point to the increased tendency for dia-
betes in South Asians compared to Caucasians [17]. Nevertheless,
the differences in telomere length of diabetes patients and controls,
including theoneobservedhere, aremuchgreater than the∼300bp
difference reported in other studies between coronary heart dis-
ease (CHD) patients and controls [33–36]. Moreover, in this study
decreasing telomere lengthwas associatedwithmore than twofold
higher risk for T2D. Having telomeres in themiddle tertile of length
was associated with 50% higher odds ratio for T2D, while having
telomeres in the lowest tertile of lengthwas associatedwith a ﬁve-
fold higher odds ratio for T2D. These data suggest an important
role of biological ageing as reﬂected by telomere shortenning in
diabetes.
Prediabetes [9] and diabetes [37] are characterised by increased
oxidative stress. In the present patient cohort higher glucose lev-
els were correlated with lower TAOS, which corresponds to higher
plasma oxidative status. Plasma TAOS measures the antioxidant
consumption, which is proportional to oxidative stress generation
and represents the net effect of many different compounds and
systemic interactions. A typical example of synergism between
antioxidants is glutathione regenerating ascorbate [38] and subse-
quently ascorbate regenerating alpha-tocopherol [39]. Therefore,
it is possible that plasma TAOS gives more biologically relevant
information than that obtained frommeasuring plasma concentra-
P2 functional SNPs in Caucasian type 2 diabetes patients.
(kb)a p-Value TAOS (%)b p-Value
5) 0.11 45.6 [35.4–54.2] 0.20 (0.08 for trend)
8) 44.3 [35.7–51.7]
6) 42.1 [34.1–48.7]
6) 0.04 43.9 [35.4–50.7] 0.17
0.24 45.8 [35.3–54.6] 0.05 (0.03 for trend)
) 44.7 [365.–52.8]
) 41.8 [32.1–48.5]
7) 0.15 44 [35.4–50.9] 0.20
4) 44.8 [42.4–47.2]
1) 0.85 42.0 [30.1–53.9] 0.03
4) 0.25 39.4 [35.6–43.1] 0.65
te the corresponding telomere length in kb.
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ions of individual antioxidants (e.g. alpha-tocopherol, ascorbate).
ithin the described sample no subject was known to take any
orm of vitamin supplements.
In an effort to reveal the factors determining the observed
horter telomere length in patients with diabetes we examined the
orrelationof lengthwith classical risk factors andplasmaoxidative
tress as reﬂected by TAOS measures. As we hypothesised, telom-
re length was signiﬁcantly correlated with measures of oxidative
tress, with higher levels of systemic oxidative stress being asso-
iated with shorter telomeres in leukocytes. This observation in
lasma is likely to be representative of the processes involved in
he development and progress of T2D in other tissues, such as the
ancreatic islets. Leukocyte telomere length has been shown to be
epresentative of that in vascular wall cells [40] and thus inter-
ndividual differences in leukocyte telomere length probably apply
o those of other cell types like beta cells. Oxidative DNA damage
nd up-regulated DNA repair mechanisms have been observed in
eta cell in T2D [41], and an inverse relationship between beta cell
olume density and levels of DNA oxidation products has been
eported [42]. Our data, coupled with these experiments, sup-
ort the theory that hyperglycaemia-induced oxidative stress may
ccelerate local and systemic senescence process, as reﬂected by
elomere dynamics.
Worthy of remark is that no other T2D risk factor was asso-
iated with the length of telomeres in patients, which suggests
hat plasma oxidative stress levels represent the oxidative bur-
en conferred by all risk factors collectively and thus the only one
ound to signiﬁcantly correlate with telomere length. The present
bservation of shortened telomeres in T2D subjects could also be
ttributed to increased cell turnover induced by chronic inﬂamma-
ory responses involved in diabetes development and progression
nd therefore, markers of inﬂammation might be associated with
elomere length [43]. To examine this possibility we looked at the
orrelation with C-reactive protein (CRP) levels, but it was not sig-
iﬁcant, conﬁrming also the ﬁndings of Sampson et al. [15]. This
ither implies that a single plasmameasure of CRP is not represen-
ative of the chronic inﬂammation underlying diabetes, or that, in
iabetes, oxidative stress is such that it may over ride any effect
f inﬂammation on telomeres. Cigarette smoking and obesity has
een previously linked to telomere shortening, but no such associ-
tion was detected here [14]. A possible reason for the discrepancy
ith our ﬁndings is that our study cohort consists of T2D patients
ho are under hyperglycaemia-induced oxidative stress, in con-
rast to the healthy subjects included in the study of Valdes et al.,
nd this may mask the effect of obesity or smoking on telomeres.
en have been reported to have shorter telomeres than women of
he same age [43]. In our sample, women had longer age-adjusted
elomeres than men but this difference was not signiﬁcant, possi-
ly due to the fact thatmost of thesewomenwere postmenopausal.
n oestrogen-responsive element exists in telomerase, the enzyme
hat replaces telomeric loss in progenitor cells [44]; thus hormonal
hanges may inﬂuence telomerase to maintain telomere length in
he progenitor cells after menopause.
Interestingly, measures of diabetes severity such as the age of
nset and the duration of the disease were not associated with
ifferences in length. However, T2D in most cases has a silent
nset; therefore the age of onset cannot be deﬁned with preci-
ion in contrast to other diseases as CHD where speciﬁc overt
ymptoms as stable or unstable angina pectoris or myocardial
nfarction indicate the disease onset. In addition, we believe that
uration of diabetes is not representative of the severity of dia-
etes in the present cohort, since we were unable to evaluate
hether and for how long glycaemia was effectively controlled
ith treatment. Uziel et al. evaluated arterial and blood mononu-
lear cell telomere length in diabetic patients and found that
lycaemic control attenuated the shortening, but in the presentosis 209 (2010) 42–50
study it was not possible to examine this [16]. A better indicator
of diabetes severity and worsening is probably the complications
of the disease as kidney failure, blindness, and cardiovascular dis-
ease or the increasing need for hypoglycaemic treatment. Indeed,
shorter telomeres were signiﬁcantly associated with higher odds
ratio for CHD in our patients (compared to the highest tertile of
telomere length, OR for the lowest tertile of telomere length: 1.67
(1.04–2.69) and OR for the middle tertile of telomere length: 1.33
(0.82–2.16), p=0.03). Records on other T2D complicationswere not
available.
To examine in more depth the association of telomere length
with oxidative stress in patients with diabetes, we evaluated in
this study for the ﬁrst time the effect of functional UCP2 variants.
UCP2 is an established negative regulator of mitochondrial ROS
overproduction [18] and its function has been linked to diabetes
development [22]. Herewe show that those carrying the functional
promoter variant−866AofUCP2have shorter telomeres. Theminor
allele −866A has been previously shown to interact with smoking
to increase oxidative stress [23]. Considering this, and that in the
present diabetes patients plasma oxidative stress was correlated
with shorter telomere length, it is likely that the observed effect
of the A allele on telomeres is due to its association with greater
mitochondrial ROS production. In this case, such genetic variants
are useful to provide a good indicator of the mitochondrial ROS
effect on telomere length, since genetic predisposition to higher
ROS is exerting its effect throughout life. On the other hand, it is
believed that the association of UCP2 with T2D is caused by a pan-
creatic effect of UCP2 on insulin secretion. UCP2 is involved in the
glucose-induced insulin secretion, through the uncoupling of ATP
production from glucose metabolism. The uncoupling of the ATP
production from glucose catabolism reduces the ATP production
which in turn results in lower ATP/ADP ratio in the pancreatic cell
and therefore decreased insulin secretion [45]. Thus, one cannot
exclude the possibility of UCP2 being involved in cell senescence
in T2D as reﬂected by the telomere dynamics here, through a path-
way triggered by disturbed insulin secretion in addition or not to
disturbed regulation of ROS.
A plausible mechanism of the situation in subjects who devel-
oped T2D may be that hyperglycaemia in the prediabetic state
induceshighoxidative stress,which in turn causes oxidative telom-
eric DNA damage and consequent shortened telomeres, which
eventually lead to premature senescence. This theory is compatible
with the beta cell failure in T2D and also the vascular endothelial
and smoothmuscle cell senescence,which promotes atherogenesis
in hyperglycaemic patients.
Another very interesting ﬁnding of the present study is the eth-
nical diversity in telomere length among T2D patients. These data
conﬁrm the recent observation of Hunt et al. [46] that Africans have
longer telomeres than Caucasians, but also show that South Asians
have similar telomere length to Caucasians. Hunt et al. showed in
their study [46] that the rate of age-dependent telomere short-
ening was faster in Africans than in Caucasians. Such evidence
supports the theory that Africans are more likely to be born with
longer telomeres and is in accordancewithpreviously reported evi-
dence of a high degree of genetic determination in telomeric length
[47].
In previous studies of ours and others, family history of CHD has
been associatedwith shorter telomere length [26,48], hence family
history of T2D might also be partly expressed through inherited
short telomeres. This theory could not be examined as no such data
were available in the present study. The ethnic differences seen in
telomere length though imply an important genetic component in
its determination. Taking all these into account one could speculate
that oxidative stress is having an effect on the length of telomeres,
but the inter-individual variability is, to a large degree, determined
by the age of the individual and the telomere length at birth [47].
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he role of genetic predisposition to shorter telomeres in subjects
rone to develop diabetes with regard to environmental factors
eeds further investigation.
Limitations of our study need to be considered. The possibility
hat an unmeasured factor, such as other inﬂammation markers or
ifestyle factors might confound the observed effects of oxidative
tress or genetic variation on telomere length cannot be excluded.
he absence of data on T2D complications, other than CHD, and
he increasing need for hypoglycaemic treatment did not allow us
o examine the association of the disease severity and telomere
ength. Moreover, this study does not include any data on telom-
re loss over time, as all measurements were taken at a certain
ime point and therefore the rate of telomere attrition in diabetes
atients couldnot be addressed. Finally, nodeﬁnite conclusions can
emade onwhether the observed shorter telomeres in patients are
cause or a consequence of diabetes since this is a case–control
tudy.
. Conclusion
This study showed that T2D is associatedwith shorter telomeres
nCaucasians andmoreover provided suggestive evidence for a link
etween systemic oxidative stress and mitochondrial production
f ROS with the shorter telomeres in T2D patients. Thus, telomere
engthmight be of use as amarker of cell oxidative damage andbio-
ogical age, providing a valuable tool in the management of T2D. A
rospective evaluation of T2D risk in relation to leukocyte telom-
re length could shed light on the question of whether telomere
hortening is a cause or a consequence of diabetes, and provide an
nsight to the potential of using telomere length for the risk assess-
ent of T2Ddevelopment. Finally, in vitro investigation of theUCP2
own-regulation will establish the role of this gene in determin-
ng the intracellular oxygen species levels, the oxidative-induced
elomere loss and the consequent cell senescence.
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